Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 6/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31453800 | 0.93 | OPRM1 (0.40) | MMEPDCD1LG2CD274OPRD1OPRM1 | |
| SCHEMBL29961849 | 0.91 | MME (0.43) | MMEPDCD1LG2CD274OPRD1OPRM1 | |
| SCHEMBL8527615 | 0.91 | MME (0.43) | MMEPDCD1LG2CD274OPRD1OPRM1 | |
| SCHEMBL8527609 | 0.91 | MME (0.43) | MMEPDCD1LG2CD274OPRD1OPRM1 | |
| SCHEMBL30312061 | 0.91 | BACE1 (0.46) | BACE1BACE2 | |
| SCHEMBL30254475 | 0.91 | OPRM1 (0.39) | MMEPDCD1LG2CD274OPRD1OPRM1 | |
| SCHEMBL30974040 | 0.91 | OPRM1 (0.42) | MMEPDCD1LG2CD274OPRD1OPRM1 | |
| SCHEMBL30973091 | 0.90 | BACE1 (0.43) | PDCD1LG2CD274OPRD1BACE1BACE2 | |
| Water SCHEMBL29655402 | 0.90 | MME (0.43) | MMEPDCD1LG2CD274OPRD1OPRM1 | |
| SCHEMBL29980611 | 0.89 | OPRM1 (0.36) | MMEOPRD1OPRM1BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583922-B2 | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | NOVIMMUNE SA (CH) | 2026-03-24 | — | — | US | claimed |
| US-12448444-B2 | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | NOVIMMUNE SA (CH) | 2025-10-21 | — | — | US | claimed |
| US-20240230663-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR PROFILING OR PREDICTING AN IMMUNE RESPONSE | AVAIL BIO INC (US) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583922-B2 | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | CD47, PDCD1LG2, CD274 | MME 4248/4885PDCD1LG2 2/4885CD274 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.